Chardan Capital analyst Keay Nakae upgrades ProQR Therapeutics (NASDAQ:PRQR) from Neutral to Buy and announces $2 price target.
Chardan Capital Upgrades ProQR Therapeutics to Buy, Announces $2 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.